Market Overview

Why Marinus Pharmaceuticals Is Trading Higher Today

Share:
Why Marinus Pharmaceuticals Is Trading Higher Today

Marinus Pharmaceuticals (NASDAQ: MRNS) shares are trading higher on Thursday after the company announced it has received FDA rare pediatric disease designation for Ganaxolone for the treatment of CDKL5 deficiency disorder.

Marinus Pharmaceuticals is a clinical stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics.

The company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

Marinus Pharmaceuticals shares were trading up 6.29% at $1.69 at time of publication on Thursday. The stock has a 52-week high of $3.50 and a 52-week low of $1.01.

 

Related Articles (MRNS)

View Comments and Join the Discussion!

Posted-In: why it's movingNews Penny Stocks Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com